相关实验视频
Updated: Jul 16, 2025

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.6K
在减肥手术前在高风险患者中使用GLP-1激动剂:一项队列研究
Malynn Ilanga1, Jessica C Heard2, James McClintic1
1Department of Surgery, University of Oklahoma at Tulsa, 1919 S. Wheeling Ave. Ste. 600, Tulsa, OK, 74104, USA.
Surgical endoscopy
|September 12, 2023
概括
葡萄糖类-1 (GLP-1) 激动剂在减肥手术前显著增加了体重减轻,患者的体重指数 (BMI) 超过50公斤/平方米. 这种方法是安全的,不会延迟手术,也不会增加并发症.
科学领域:
- 代谢和腹部手术的代谢和腹部手术
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 体重指数 (BMI) 超过50公斤/平方米的患者在减肥手术 (BS) 中面临更高的风险.
- 术前减肥通常是必要的,但对于这一群体来说,实现减肥可能是具有挑战性的.
- 已知类似葡萄糖-1 (GLP-1) 激动剂在BS后有效减肥.
研究的目的:
- 为了评估使用GLP-1激动剂在患有BMI>50 kg/m2的患者的预康复中使用GLP-1激动剂的安全性和有效性.
- 为了确定GLP-1激动剂是否能促进手术前的减肥,而不会影响手术时间表或增加风险.
主要方法:
- 减肥手术患者的回顾性审查,BMI>50 kg/m2.
- 对接受手术前GLP-1治疗的患者与没有接受GLP-1治疗的患者进行比较.
- 评估手术前的BMI,体重变化,手术前的时间和术后并发症.
主要成果:
- 与对照组 (2,9 分) 相比,GLP-1 主动剂的使用与显著更大的BMI降低 (5.5 分) 相联系.
- 两组之间没有观察到手术时间的显著差异.
- 没有报告GLP-1相关的并发症,手术后并发症发生率在各组之间相似.
结论:
- 手术前的GLP-1主激素治疗导致在减肥手术前BMI>50kg/m2的患者减肥.
- 这种方法是安全的,不会延长手术的时间,也不会增加并发症率.
- 需要进一步的研究来评估在高风险人群中术前使用GLP-1激动剂的长期益处.
相关概念视频
Glucagon-like Receptor Agonists
357
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
357
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Oral Hypoglycemic Agents: Glinides
183
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
183
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
203
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
203
Oral Hypoglycemic Agents: Sulfonylureas
235
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
235

